The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prospective study of oncogenic mutations in circulating cell-free DNA (cfDNA) using a multiplex sequencing platform for patient (pt) allocation to phase I clinical trials.
Michael Ong
No relevant relationships to disclose
Joaquin Mateo
No relevant relationships to disclose
Lorna Pope
No relevant relationships to disclose
Amy Mulick Cassidy
No relevant relationships to disclose
Timothy Anthony Yap
No relevant relationships to disclose
Geraldine Perkins
No relevant relationships to disclose
Ruth Riisnaes
No relevant relationships to disclose
Penelope Flohr
No relevant relationships to disclose
Khin Thway
No relevant relationships to disclose
Sadiya Saeed
No relevant relationships to disclose
Katie Ann Denholm
No relevant relationships to disclose
Helen Nicole Toloui
No relevant relationships to disclose
Kirsty Moran
No relevant relationships to disclose
Jen Kate Lewis
No relevant relationships to disclose
Jesus Corral Jaime
No relevant relationships to disclose
Andrea Biondo
No relevant relationships to disclose
L Rhoda Molife
No relevant relationships to disclose
Stanley B. Kaye
No relevant relationships to disclose
Udai Banerji
No relevant relationships to disclose
Johann Sebastian De Bono
No relevant relationships to disclose